PRE PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d

PRE ▲ +14.55% at T+60d

LONG call ✓ call won +14.55% · α vs SPY +1.77% · entry $17.80 → $20.39

Currently $20.93 · +17.58% from $17.80 entry

Entry anchored
Mar 5, 03:59 PM ET
via Databento tick

T+1d

+15.11%

call +15.11% · α +14.27%

$20.49

settled 3mo ago

T+5d

+16.40%

call +16.40% · α +17.93%

$20.72

settled 3mo ago

T+20d

+12.13%

call +12.13% · α +14.18%

$19.96

settled 2mo ago

T+60d

+14.55%

call +14.55% · α +1.77%

$20.39

settled 8d ago

Price Chart

Loading chart...

Executive Summary

Prenetics announced a $40 million share repurchase program and disclosed that its management and board have already committed $2.75 million in personal capital to buying shares. The company cites strong liquidity of $164 million, zero debt, and IM8's growth trajectory toward $180M–$200M in 2026 revenue as justification, arguing the stock is undervalued at an enterprise value of $89 million. The move signals strong insider conviction amid a strategic pivot focused entirely on the IM8 health brand.

Key Financial Metrics

Guidance

$180M-$200M

initiated

Deal Value

$40.0M

Actionable Insight

The combination of insider buying, a substantial buyback, strong liquidity, and aggressive revenue targets suggests significant undervaluation. Traders should monitor buyback execution and upcoming earnings for IM8 revenue trends. A sub-0.5x revenue multiple on a growing, profitable-path business is unusually low and may correct if execution continues.

Key Facts

Board authorized $40 million share repurchase program over 12 months.
Management and board collectively committed $42.75 million to stock (including $2.75M in personal purchases).
CEO Danny Yeung personally bought $750,000 of stock in February 2026.
Company has $164 million in adjusted liquidity and zero debt as of March 1, 2026.
IM8 revenue guidance: $180M–$200M for full-year 2026.
Targeting adjusted EBITDA profitability by Q4 2027.
Enterprise value is ~$89 million, implying a sub-0.5x multiple on 2026 revenue.

Financial Impact

Up to $40 million in capital return via buybacks; $164 million liquidity supports both growth and repurchases. IM8 alone is guiding for $180M–$200M in 2026 revenue.

cashshares outstandingEPS (potential accretion)enterprise valueliquidity

Risk Factors

Forward-looking guidance may not materialize; IM8 revenue and EBITDA targets are not guaranteed.
Adjusted liquidity includes volatile components like digital assets ($34.2M) and fair value financial assets subject to change.
Buyback program is discretionary and may be suspended or executed slowly.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3251004

5 reports for PRE

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PRE — sortable, filterable
	Type				Now
Jun 4, 2026 5d ago	Press Release BULLISH ★ 6/10	$20.79 $19.86	▼ −4.47%	▼ −1.88%	$20.93 (+0.67%)
May 14, 2026 26d ago	Press Release MIXED ★ 6/10	$17.59 $15.61	▼ −11.26%	▼ −10.03%	$20.93 (+18.99%)
May 8, 2026 4w ago	Press Release NEUTRAL ★ 3/10	$16.16 $17.55	▲ +8.60%	▲ +8.37%	$20.93 (+29.52%)
Mar 24, 2026 11w ago	Press Release MIXED ★ 5/10	$22.15 $21.56	▼ −2.66%	▼ −3.23%	$20.93 (−5.51%)
Mar 6, 2026 13w ago	Press Release BULLISH ★ 7/10	$17.80 $20.49	▲ +15.11%	▲ +14.27%	$20.93 (+17.58%)

US Market Status

Market Closed — Opens Thu (10h 6m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access